Infection of a cell by HIV-1 proceeds through a series of steps, each of which defines a potential target for antiviral drug intervention. Current drugs target key viral activities catalyzed by the protease, reverse transcriptase, and integrase enzymes, but emergence of drug resistance calls for continual development of new drugs with novel modes of action. HIV-1 depends on interactions with numerous cellular proteins as it replicates and maraviroc, a drug that disrupts the interaction between the viral envelope glycoprotein and cellular surface CCR5 receptor, is an approved inhibitor of a virus-cell interaction that blocks the ability of the virus to enter the cell. Also crucial to HIV-1 replicatin is the ability for the preintegration complex intermediate that houses the integrase and reverse transcript to access the chromosomes inside the cell nucleus, where viral DNA integration takes place. Lentiviruses like HIV-1 use an energy-dependent process to transport their preintegration complexes through nuclear pore complexes that riddle the biphasic nuclear envelope, though the molecular mechanisms underlying HIV-1 nuclear transport are poorly understood. Work supported by this renewal grant application identified numerous cellular proteins as potential critical cofactors of HIV-1 replication and a significant number of these, including transportin-3, nucleoporin 153, and nucleoporin 358 were accordingly implicated in preintegration complex nuclear import due to their known functions within the cell. Subsequent work indeed confirmed this contention, though it remains unclear how these and other cellular and viral proteins precisely dictate HIV-1 preintegration complex nuclear import. Using numerous virology, biochemical, and genetic approaches, the work proposed herein will determine the mechanisms of HIV-1 nuclear import, focusing on novel protein interactions between the virus and host cellular components that are essential for the process. Such discoveries will define new targets for the development of inhibitors that block critical HIV-host interactions, which would be expected to increase the breadth of future antiviral armaments in the ongoing battle to control the spread of HIV/AIDS.

Public Health Relevance

Despite HAART successes, drug resistance emerges due to the inherent viral genetic barrier required to build resistance to any given compound plus associated toxicity of compound use, which significantly affects patient compliance. These observations highlight the ongoing need to develop new antiviral inhibitors, and crucial interactions between HIV-1 and cellular cofactors have been highlighted in recent years as novel drug targets. This proposal will uncover novel details of how the HIV-1 preintegration complex, a critical viral replication intermediate, accesses the cellular nucleus where viral integration occurs, which will define novel targets for antiviral drug development moving forward.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
4R01AI052014-14
Application #
9011985
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Church, Elizabeth S
Project Start
2002-04-01
Project End
2017-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
14
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
Zhu, Yong; Wang, Xiuye; Forouzmand, Elmira et al. (2018) Molecular Mechanisms for CFIm-Mediated Regulation of mRNA Alternative Polyadenylation. Mol Cell 69:62-74.e4
Achuthan, Vasudevan; Perreira, Jill M; Sowd, Gregory A et al. (2018) Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration. Cell Host Microbe 24:392-404.e8
Engelman, Alan N; Singh, Parmit K (2018) Cellular and molecular mechanisms of HIV-1 integration targeting. Cell Mol Life Sci 75:2491-2507
Puray-Chavez, Maritza; Tedbury, Philip R; Huber, Andrew D et al. (2017) Multiplex single-cell visualization of nucleic acids and protein during HIV infection. Nat Commun 8:1882
Yamashita, Masahiro; Engelman, Alan N (2017) Capsid-Dependent Host Factors in HIV-1 Infection. Trends Microbiol 25:741-755
Wang, Weifeng; Zhou, Jing; Halambage, Upul D et al. (2017) Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein. J Virol 91:
Lesbats, Paul; Engelman, Alan N; Cherepanov, Peter (2016) Retroviral DNA Integration. Chem Rev 116:12730-12757
Zurnic, Irena; Hütter, Sylvia; Rzeha, Ute et al. (2016) Interactions of Prototype Foamy Virus Capsids with Host Cell Polo-Like Kinases Are Important for Efficient Viral DNA Integration. PLoS Pathog 12:e1005860
Serrao, Erik; Cherepanov, Peter; Engelman, Alan N (2016) Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites. J Vis Exp :
Saito, Akatsuki; Ferhadian, Damien; Sowd, Gregory A et al. (2016) Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74. J Virol 90:5808-5823

Showing the most recent 10 out of 50 publications